Core Insights - The report from Southwest Securities highlights that by 2025, overseas cloud providers will emphasize "cloud service shortages" and "expanding data centers based on demand signals," while increasingly focusing on the commercialization of AI applications. AI investment is transitioning from FOMO CapEx to ROI CapEx [1][2] Group 1: AI Investment Trends - Overseas tech giants are expected to see significant capital expenditure growth in 2024-2025, with increased investment from AI startups and an upward revision of future spending expectations. The industry is currently facing cash flow pressures, prompting tech firms to explore various data center construction methods and financing options [1] - In 2024, some overseas cloud providers indicate that the risk of under-investment in AI is far greater than the risk of over-investment, with AI investments accompanied by FOMO sentiment [2] Group 2: Data Center Efficiency - Data centers are facing power capacity limitations, leading cloud providers to emphasize maximizing tokens output efficiency per watt. This involves optimizing hardware components such as chips, storage, and communication, as well as software stacks and system architectures to enhance computational efficiency [3] - Cloud providers are increasingly focusing on the versatility and flexibility of data center construction to accommodate various generations of GPUs and electrical components, allowing for a flexible switch between training and inference workloads [3] Group 3: AI Model Development - The engineering capabilities of large AI models are continuously improving, with a growing demand for commercializing AI products. Future iterations of AI models will focus on long text, multimodal capabilities, logical reasoning, and tool usage [4] - As the Scaling Law extends from pre-training to reinforcement learning and continuous learning, the requirements for training datasets will evolve, leading to differentiated model capabilities and the emergence of various AI use cases [4] Group 4: Cloud Business Growth - By 2025, overseas AI cloud services are expected to enter a "super large orders + long-term infrastructure" phase, with cloud order amounts ranging from billions to hundreds of billions. The remaining contract amounts for overseas cloud providers are also experiencing rapid growth, indicating a potential acceleration in AI cloud service expansion [5] - The revenue growth of cloud businesses will heavily depend on the pace of capacity rollout, with expectations for accelerated growth as computational capacity is gradually released by 2026 [5]

西南证券主要观点如下： 回顾2025年 2025年初截至12月31日，申万家电指数指数上涨9.1%，在申万行业中涨幅排名第24。 西南证券发布研报称，整体而言，2026年在高基数及需求提前消化的大背景下，家电行业仍将处于恢复 期，但也迎来了"国补"和"关税"两大事件影响下的新常态。该行认为中国家电行业作为毫无争议的世界 第一，其中，优秀的公司及蕴含的新赛道都仍存长期投资价值。建议关注主线一：逆境方显龙头本色， 关注龙头公司高性价比，高分红。主线二：关注出海赛道。主线三：消费升级仍是长久趋势，体验提升 +创新品类值得关注 整体而言，2026年在高基数及需求提前消化的大背景下，家电行业仍将处于恢复期，但也迎来了"国 补"和"关税"两大事件影响下的新常态。该行认为中国家电行业作为毫无争议的世界第一，其中，优秀 的公司及蕴含的新赛道都仍存长期投资价值。 主线一：逆境方显龙头本色，关注龙头公司高性价比，高分红 基本面来看，从2025年下半年来看，国补收紧，边际效果递减已经定局。国内需求的提前透支，以及地 产及消费习惯变化导致的需求减少，该行认为内销目前需要一个较长的恢复期，因此，一方面外销占比 更高的个股受到的边际影响 ...

Core Viewpoint - The report from Southwest Securities indicates that the performance of the light industry sector in 2025 is expected to be flat, with cyclical and traditional manufacturing valuations under pressure, while packaging, exports, and personal care sectors show differentiated performance [1] 2025 Sector Review - In 2025, the light industry sector experienced relatively flat performance, with traditional cyclical and manufacturing companies facing valuation pressure. However, the packaging and printing sectors benefited from price increases and cross-industry transformations, leading to better stock performance [1] - The export sector showed some differentiation due to tariff policy disruptions, with companies that have balanced production capacity, strong demand resilience, and low tariff impact performing better [1] - The personal care sector achieved excess returns in the first half of the year but entered a valuation digestion phase in the second half due to intensified competition in e-commerce channels. However, domestic brands are expected to continue their growth trajectory due to product structure optimization and channel expansion [1] 2026 Stock Selection Strategy - The focus will be on undervalued cyclical assets as valuation recovery is anticipated amid changes in the bulk commodity cycle, gradually realizing allocation value [2] - There is a need to balance the valuation and growth potential of new consumption and export sectors, favoring high-growth or low-valuation, high-safety stocks [2] - Four main lines of focus for stock selection include: 1. Gradually emphasizing undervalued cyclical stocks, particularly in the paper sector, which is expected to see price increases driven by "anti-involution" and traditional peak season factors, with net profit per ton likely to recover [2] 2. Export stocks with strong demand resilience and manufacturing capabilities are still considered valuable for allocation, especially those with good growth potential in niche categories and minimal tariff impact [2] 3. Domestic personal care brands are expected to see upward trends in market share and growth potential due to rapid product iteration and competitive pricing [2] 4. New consumption trends in AI glasses, new tobacco products, pet supplies, and trendy toys are expected to continue their upward trajectory, contributing to the growth of the consumption sector [2] Recommended Stocks - Recommended stocks include Sun Paper, Bohui Paper, Weigao Medical, Baiya Co., Nobon Co., Yiyi Co., Mengbaihe, and Gujia Home [3]

证券代码：600369 证券简称：西南证券 公告编号：临2026－001 西南证券股份有限公司 关于控股股东变更进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、本次控股股东变更的基本情况 2025 年 1 月，为深入贯彻落实党的二十届三中全会精神和重庆市委六届四 次五次六次全会精神及重庆市委、市政府关于突出主责主业强化核心功能整合优 化改革攻坚的工作部署，重庆渝富控股集团有限公司（以下简称渝富控股）通过 国有股权无偿划转受让重庆渝富资本运营集团有限公司（以下简称渝富资本）持 有的西南证券股份有限公司（以下简称公司）1,960,661,852 股股份，占公司总股 本的 29.51%（有关内容详见相关信息披露义务人于 2025 年 1 月 8 日在上海证券 交易所网站披露的《西南证券股份有限公司收购报告书》）。 本次收购完成后，渝富资本将不再持有公司股权，渝富控股将直接持有公司 1,960,661,852 股，占公司总股本的 29.51%，为公司控股股东。公司实际控制人 仍为重庆市国有资产监督管理委员会。 ...

重要股东主动延长禁售期，彰显长期信心 主动延锁反映了主要利益相关方对公司未来发展的高度认可，也间接确认了企业AI医疗战略及中长期 成长空间。第二，核心股东合计所持股份占比极高，禁售期延续在一定程度上稳定了市场增长预期，有 助于遏制短期股票供给压力，对股价有正面支持效应。高管及核心技术团队通过员工持股平台深度绑定 股权，充分调动团队积极性，有利于巩固业务创新动能。 深度绑定自研"星火"大模型，具备全栈自主可控的技术壁垒 2025年3月，公司正式发布基于深度推理技术的"讯飞星火医疗大模型X1"。该模型是当前唯一完全采用 全国产算力训练完成的医疗深度推理大模型。在真实场景测试中，其全科辅助诊断合理率达到94.0%。 2025年7月，讯飞星火医疗大模型完成能力升级，多项性能指标得到进一步提升。具体而言，全科辅助 诊断合理率提升至95.0%，体检报告解读合理率提升至86.3%，健康咨询解答率提升至91.5%，院端心血 管内科主要诊断合理率提升至91.2%。测试表明，在关键医疗场景任务上，其表现继续大幅领先于 OpenAI o3及DeepSeek R1等国际主流模型。与多数依赖第三方或开源模型的AI应用公司不同，讯飞医疗 ...

Core Viewpoint - The AI medical market has significant potential, and iFlytek Medical Technology (02506) possesses a self-developed foundational model, continuously enhancing its performance ceiling. The company is the primary beneficiary of policy dividends and national projects in the AI medical sector, warranting ongoing attention [1]. Group 1: Shareholder Actions - Major shareholders, including the parent company iFlytek (002230) and key investors, voluntarily extended the lock-up period for their shares by one year until December 29, 2026, committing not to reduce their holdings during this period. As of the announcement date, these shareholders collectively held 52,758,395 H-shares, accounting for 68.25% of the total H-share capital and 72.86% of the total share capital [1][2]. Group 2: Technology and Product Development - In March 2025, the company launched the "iFlytek Spark Medical Model X1," the only medical deep reasoning model fully trained using domestically produced computing power. In real-world testing, its general auxiliary diagnosis accuracy reached 94.0%. By July 2025, the model's capabilities were upgraded, with the general auxiliary diagnosis accuracy improving to 95.0%, and other performance metrics also showing significant enhancements [3]. - The company’s deep reliance on its self-developed "Spark" model, based entirely on domestic computing power, provides two core advantages: strong market entry barriers due to data security and autonomy, especially in government and large public hospitals, and a feedback loop for continuous improvement of the model through accumulated data and application experience [3]. Group 3: Market and Policy Environment - The AI+medical sector is a clear direction for policy growth, with the company positioned to benefit significantly from this trend. Amid tightening fiscal and healthcare cost controls, traditional medical IT investments face pressure, while AI is recognized as a means to enhance grassroots diagnosis and optimize resource allocation, supported by various national policies [4]. - Revenue forecasts for the company are projected at 930 million yuan, 1.21 billion yuan, and 1.58 billion yuan for 2025-2027, with corresponding price-to-sales ratios of 8.5x, 6.5x, and 5x [4].

近日，银行间市场交易商协会（下称"交易商协会"）发布了《关于2025年非金融企业债务融资工具承销 业务相关会员申请从事承销相关业务市场评价结果的公告》。 设立主承销及承销业务相关部门 根据公告，华泰联合证券、摩根大通银行（中国）、星展银行（中国）、山西证券、财通证券等机构获 得了相应的业务资质。 这些机构获得的业务资质包括：非金融企业债务融资工具一般主承销商，科技创新非金融企业债务融资 工具主承销商，非金融企业债务融资工具承销商。 多家机构获得业务资质 交易商协会的公告表示，根据《银行间债券市场非金融企业债务融资工具管理办法》（中国人民银行令 〔2008〕1号发布）及《中国银行间市场交易商协会非金融企业债务融资工具承销业务相关会员市场评 价规则》（协会公告〔2024〕16号发布，下称《市场评价规则》）等自律规则，交易商协会于2025年11 月14日发布公告启动2025年非金融企业债务融资工具承销业务相关会员申请从事承销相关业务市场评价 工作。 截至申请截止日2025年11月28日，共有37家会员提交了申请材料，交易商协会秘书处依据市场评价标准 组织审核工作，形成评价结果，经交易商协会第五届债券市场专业委员会第 ...

Core Viewpoint - The announcement by the Interbank Market Dealers Association regarding the evaluation results for member applications to engage in underwriting related to non-financial corporate debt financing tools for 2025 highlights the expansion of qualified institutions in this sector [1][4]. Group 1: Qualified Institutions - Several institutions, including Huatai United Securities, JPMorgan Chase Bank (China), DBS Bank (China), Shanxi Securities, and Caitong Securities, have obtained relevant business qualifications [2][4]. - A total of 37 members submitted applications for underwriting qualifications, with 8 new members recognized as general lead underwriters for non-financial corporate debt financing tools [4][5]. - Bank of China International Securities Co., Ltd. has been designated as a lead underwriter for technology innovation non-financial corporate debt financing tools [4]. Group 2: Underwriting Business Regulations - The announcement outlines that lead underwriters and underwriters must establish dedicated departments for underwriting business, appoint specialized personnel, and develop operational procedures, risk management, and internal control systems [7]. - Lead underwriters must collaborate with independently qualified lead underwriters to conduct underwriting business, and may independently engage in underwriting after gaining sufficient experience [7]. - The Association will suspend or revoke underwriting qualifications for lead underwriters or underwriters found guilty of significant legal or regulatory violations [7]. Group 3: Membership Classification - The Association categorizes underwriters into lead underwriter members, underwriting members, and intending underwriting members, with lead underwriter members further divided into general and specialized categories [8][9]. - General lead underwriter members can engage in all categories of non-financial corporate debt financing tool underwriting, while specialized members can only handle specific categories [8]. - Intending underwriting members are those interested in participating in underwriting but are not yet classified as underwriters [9].

Core Viewpoint - The approval of 18 new brokerage firms for non-financial corporate debt financing tool underwriting qualifications enhances the competitive landscape in the fixed income market in China [1] Group 1: New Brokerage Firms Approved - The China Interbank Market Dealers Association has released the list of 2025 non-financial corporate debt financing tool underwriting qualifications, adding 18 new brokerages this year [1] - Among the new additions, six brokerages, including Caitong Securities and First Capital Securities, are designated as general lead underwriters for non-financial corporate debt financing tools [1] - Zhongyin Securities has been approved as the lead underwriter for technology innovation non-financial corporate debt financing tools, which includes the underwriting of bonds supporting technological innovation [1] Group 2: Implications for Brokerage Firms - The approval of these qualifications is expected to assist brokerages in enhancing their fixed income business layout and improving their comprehensive bond business system [1]

Group 1: Core Insights - The report from Southwest Securities indicates that by early 2025, Hong Kong-listed companies will begin to achieve business development (BD) milestones, with innovative drugs leading the market surge [1] - The Chinese innovative drug sector is expected to accelerate following the government's support for drug pricing mechanisms and the development of innovative drugs and medical devices, as highlighted in the March government work report [1] - The innovative drug sector is predicted to transition from a broad market rally to a selective stock picking phase by 2026, with a focus on three key areas: overseas expansion, brain-computer interfaces, and AI in healthcare [1] Group 2: Overseas Expansion - By December 5, 2025, the number of BD projects for Chinese innovative drugs going overseas reached 166, an increase of 54 projects compared to the entire year of 2024 [1] - The upfront payments for these projects totaled $6.3 billion, representing a growth of over 199% from 2024 [1] - The total amount for overseas projects reached $141.97 billion, an increase of over 136.8% from 2024, with over 52% of the molecules in early clinical stages [1] Group 3: Brain-Computer Interfaces - The 15th Five-Year Plan emphasizes the development of brain-computer interfaces as a new economic growth point, with several provinces introducing fee standards and including some projects in medical insurance [2] - The application of brain-computer interface technology is primarily focused on medical rehabilitation, particularly for patients with stroke and spinal cord injuries, with potential expansion into education, entertainment, and industrial sectors [2] Group 4: AI in Healthcare - Five national departments issued guidelines to promote and regulate the application of AI in healthcare, setting clear short-term (by 2027) and long-term (by 2030) goals across eight major areas [3] - AI in healthcare is entering a new phase of technological integration and industry restructuring, with key applications including AI health management, clinical decision support systems, medical imaging diagnostics, surgical robotics, genetic sequencing, and drug development [3] Group 5: Recommended Companies - The report recommends several companies for investment, including Heng Rui Medicine, BeiGene, Mindray Medical, United Imaging Healthcare, and others, indicating a diverse portfolio in the healthcare sector [4]